Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026)
Intellia Therapeutics (NTLA) reported EBITDA Margin of 647.95% for Q1 2026, up 3695.0% year-over-year from 17.07% in Q1 2025, and down 55.77% quarter-over-quarter from 415.97% in Q4 2025.
Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of EBITDA Margin data on file, last reported at 647.95% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 647.95%, up 3695.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 599.0% (up 55070.0% YoY), and the FY2025 annual result was 609.22%, up 28628.0% from the prior year.
- EBITDA Margin declined to 647.95% in Q1 2026 per NTLA's latest filing, from 415.97% in the prior quarter.
- Over five years, EBITDA Margin peaked at 6825.61% in Q4 2023 and troughed at 2115.61% in Q2 2024.
- A 5-year average of 458.41% and a median of 780.13% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin soared 2308287 bps in 2022, then slumped 784775 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 821.48% in 2022, then jumped by 931 bps to 6825.61% in 2023, then tumbled by 115 bps to 1022.14% in 2024, then soared by 59 bps to 415.97% in 2025, then plunged by 56 bps to 647.95% in 2026.
- Business Quant data shows NTLA's EBITDA Margin at 647.95% in Q1 2026, 415.97% in Q4 2025, and 732.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -647.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -647.95% |
| Dec 31, 2025 | -415.97% |
| Sep 30, 2025 | -732.75% |
| Jun 30, 2025 | -713.65% |
| Mar 31, 2025 | -684.89% |
| Dec 31, 2024 | -1,022.14% |
| Sep 30, 2024 | -1,440.68% |
| Jun 30, 2024 | -2,115.61% |
| Mar 31, 2024 | -374.14% |
| Dec 31, 2023 | 6,825.61% |
| Sep 30, 2023 | -1,016.74% |
| Jun 30, 2023 | -918.57% |
| Mar 31, 2023 | -780.13% |
| Dec 31, 2022 | -821.48% |
| Sep 30, 2022 | -852.13% |
| Jun 30, 2022 | -728.23% |
| Mar 31, 2022 | -1,353.55% |
| Dec 31, 2021 | -651.12% |
| Sep 30, 2021 | -23,935.00% |
| Jun 30, 2021 | -1,050.49% |